CCJ Stock Analysis: Cameco | NYSE
Uranium | NYSE, USA | Market Cap: 40.775m USD | 12M Return: 25.5% | CA13321L1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 352M
EPS Trend: 74.0%
Qual. Beats: -1
Rev. Trend: 93.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cameco Corporation (NYSE: CCJ) is a Canadian-based uranium producer supplying fuel for nuclear power generation across the Americas, Europe, and Asia. The company operates through three segments: Uranium (exploration, mining, milling, and sale of uranium concentrate), Fuel Services (refining, conversion, and fabrication of uranium concentrate and conversion services), and Westinghouse (a nuclear reactor technology original equipment manufacturer offering outage and maintenance, engineering support, instrumentation and controls, plant modification services, and reactor components). Customers are primarily nuclear utilities, with additional sales to government agencies. Cameco was incorporated in 1987 and is headquartered in Saskatoon, Canada, with its shares listed on the NYSE since 1996.
The companys vertically integrated structure spans the front-end of the nuclear fuel cycle, from raw uranium concentrate through refined and fabricated fuel products, alongside reactor technology and services. Nuclear power provides a low-carbon baseload energy source, and Camecos inclusion in the GICS Energy sector reflects its role in fuel production rather than electricity generation itself.
- Uranium spot prices surge on AI-driven nuclear power demand
- Westinghouse acquisition expands reactor services revenue stream
- Russian uranium import ban tightens Western utility supply
| Net Income: 355.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -4.22 > 1.0 |
| NWC/Revenue: 47.38% < 20% (prev 33.42%; Δ 13.97% < -1%) |
| CFO/TA 0.09 > 3% & CFO 920.4m > Net Income 355.1m |
| Net Debt (-103.9m) to EBITDA (863.8m): -0.12 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.6m) vs 12m ago 0.01% < -2% |
| Gross Margin: 27.90% > 18% (prev 26.54%; Δ 1.36% > 0.5%) |
| Asset Turnover: 34.95% > 50% (prev 37.26%; Δ -2.31% > 0%) |
| Interest Coverage Ratio: 7.09 > 6 (EBIT TTM 557.6m / Interest Expense TTM 78.6m) |
| A: 0.16 (Total Current Assets 2.44b - Total Current Liabilities 798.8m) / Total Assets 10.3b |
| B: 0.37 (Retained Earnings 3.77b / Total Assets 10.3b) |
| C: 0.06 (EBIT TTM 557.6m / Avg Total Assets 9.94b) |
| D: 2.26 (Book Value of Equity 7.14b / Total Liabilities 3.16b) |
| Altman-Z'' = 4.99 = AAA |
| DSRI: 1.04 (Receivables 354.3m/351.5m, Revenue 3.47b/3.57b) |
| GMI: 0.95 (GM 26.54% / 27.90%) |
| AQI: 0.91 (AQ_t 0.43 / AQ_t-1 0.47) |
| SGI: 0.97 (Revenue 3.47b / 3.57b) |
| TATA: -0.05 (NI 355.1m - CFO 920.4m) / TA 10.3b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of August 12, 2026, the stock is trading at USD 97.31 with a total of 1,766,846 shares traded. Over the past week, the price has changed by +8.46%, over one month by +1.38%, over three months by -19.00% and over the past year by +25.53%.
Current recommended Stop Loss: 90.60 (which is 6.9% or 1.6 ATR below the current price).
Cameco has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy CCJ.
- StrongBuy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 129.6 | 33.2% |
Market Cap CAD = 56.9b (40.8b USD * 1.395 USD.CAD)
P/E Trailing = 164.2456
P/E Forward = 80.0
P/S = 11.735
P/B = 7.9648
P/EG = 1.9161
Revenue TTM = 3.47b CAD
EBIT TTM = 557.6m CAD
EBITDA TTM = 863.8m CAD
Long Term Debt = 996.8m CAD (from longTermDebt, last quarter)
Short Term Debt = 3.34m CAD (from shortTermDebt, last fiscal year)
Debt = 1.01b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -103.9m CAD (calculated: Debt 1.01b - CCE 1.11b)
Enterprise Value = 56.8b CAD (56.9b + Debt 1.01b - CCE 1.11b)
Interest Coverage Ratio = 7.09 (Ebit TTM 557.6m / Interest Expense TTM 78.6m)
EV/FCF = 106.2x (Enterprise Value 56.8b / FCF TTM 534.4m)
FCF Yield = 0.94% (FCF TTM 534.4m / Enterprise Value 56.8b)
FCF Margin = 15.38% (FCF TTM 534.4m / Revenue TTM 3.47b)
Net Margin = 10.22% (Net Income TTM 355.1m / Revenue TTM 3.47b)
Gross Margin = 27.90% ((Revenue TTM 3.47b - Cost of Revenue TTM 2.50b) / Revenue TTM)
Gross Margin QoQ = 21.06% (prev 35.68%)
Tobins Q-Ratio = 5.51 (Enterprise Value 56.8b / Total Assets 10.3b)
Interest Expense / Debt = 7.79% (Interest Expense 78.6m / Debt 1.01b)
Taxrate = 24.65% (116.1m / 470.8m)
NOPAT = 420.2m (EBIT 557.6m * (1 - 24.65%))
Current Ratio = 3.06 (Total Current Assets 2.44b / Total Current Liabilities 798.8m)
Debt / Equity = 0.14 (Debt 1.01b / totalStockholderEquity, last quarter 7.14b)
Debt / EBITDA = -0.12 (Net Debt -103.9m / EBITDA 863.8m)
Debt / FCF = -0.19 (Net Debt -103.9m / FCF TTM 534.4m)
Total Stockholder Equity = 6.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.57% (Net Income 355.1m / Total Assets 10.3b)
RoE = 5.49% (Net Income TTM 355.1m / Total Stockholder Equity 6.47b)
RoCE = 7.46% (EBIT 557.6m / Capital Employed (Equity 6.47b + L.T.Debt 996.8m))
RoIC = 4.50% (NOPAT 420.2m / Invested Capital 9.33b)
WACC = 13.03% (E(56.9b)/V(57.9b) * Re(13.16%) + D(1.01b)/V(57.9b) * Rd(7.79%) * (1-Tc(0.25)))
Discount Rate = 13.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 23.96 | Cagr: 0.14%
[DCF] Terminal Value 57.78% ; FCFF base≈681.2m ; Y1≈597.4m ; Y5≈482.6m
[DCF] Fair Price = 10.35 (EV 4.41b - Net Debt -103.9m = Equity 4.51b / Shares 435.5m; r=13.03% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 73.97 | EPS CAGR: 39.35% | SUE: -0.86 | # QB: -1
Revenue Correlation: 93.62 | Revenue CAGR: 18.02% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.34 | Chg30d=-1.32% | Revisions=+44% | Analysts=8
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=-7.37% | Revisions=+55% | GrowthEPS=+4.5% | GrowthRev=+0.3%
EPS next Year (2027-12-31): EPS=2.64 | Chg30d=-0.74% | Revisions=+18% | GrowthEPS=+75.3% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: +48% (up=17, down=5)